Aurora kinase-IN-1

Aurora kinase-IN-1

• UNSPSC Description: Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents[1].
• Target Antigen: Apoptosis; Aurora Kinase
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/aurora-kinase-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: CCOC(/C(C1=O)=C/NC2=NC(C3=CC=C(C(OC)=C3)OC)=CC(C4=CC=C(C=C4)Br)=N2)OC5=C1C=C(Br)C=C5
• Molecular Weight: 667.34
• References & Citations: [1]Shin SY, et al. Design, synthesis, and biological activities of 3-((4,6-diphenylpyrimidin-2-ylamino)methylene)-2,3-dihydrochromen-4-ones [published online ahead of print, 2022 Jan 20]. Bioorg Chem. 2022;120:105634.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported